You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 DNA damage measured by 53BP1 in PBMCs isolated from blood of apparently healthy donors (N) and unselected breast cancer (BC) patients after exposure to 0.5 or 2 Gy of X-irradiation in vitro * or after 5 clinical fractions (BC patients)

From: Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci

Subjecta Age (years) Sex Clinical status with respect to cancer, skin reaction to RTb 0 Gy 0.5 Gy, 30’ 0.5 Gy, 24 h 2 Gy, 24 h 72 h after 5 clinical fractions
Apparently healthy donors
N-3 29 F n.d. 0.71 2.47 0.99 1.47  
N-4 58 F n.d. 0.68 2.83 0.96 1.37  
N-5 58 F n.d. 0.41 2.65 1.16 1.25  
N-6 65 F n.d. 0.35 2.48 1.07 1.73  
N-7 56 F n.d. 0.53 2.26 0.66 0.76  
N-8 48 F n.d. 0.38 2.32 0.98 1.36  
N-9 41 F n.d. 0.32 2.10 0.96 1.04  
N-10 44 F n.d. 0.50 2.46 0.79 1.02  
N-11 48 F n.d. 0.48 2.60 0.81 1.20  
N-12 43 F n.d. 0.38 2.42 0.67 0.80  
Mean 45    0.47 2.46 0.91 1.20  
± SD 12    0.13 0.20 0.16 0.29  
Breast cancer patients
BC-01 59 F BC, grade 3 0.13 0.85 n.d. 1.84 1.73
BC-04 73 F BC, grade 3 0.15 1.24 n.d. 2.61 1.68
BC-12 61 F BC, grade 3 0.11 1.19 n.d. 2.18 0.95
BC-13 55 F BC, grade 3 0.35 2.47 n.d. 2.86 1.23
BC-33 42 F BC, grade 3 0.35 0.87 n.d. 2.78 1.60
BC-39 55 F BC, grade 1 0.32 2.56 0.75 1.41 0.90
BC-40 77 F BC, grade 2 0.61 2.43 0.62 0.61 0.78
BC-41 54 F BC, grade 1 0.97 2.36 1.11 1.34 0.91
BC-42 49 F BC, grade 1 0.19 2.48 0.76 1.68 0.80
BC-43 62 F BC, grade 2 0.33 1.99 0.92 1.58 0.42
BC-44 59 F BC, grade 1 0.24 2.08 1.25 2.16 0.58
BC-45 51 F BC, grade 1 0.20 1.73 1.20 2.12 0.77
BC-46 62 F BC, grade 1 0.33 2.73 1.34 0.56 0.74
BC-47 30 F BC, grade 2 0.26 2.57 1.38 0.98 0.65
BC-48 71 F BC, grade 2 0.79 3.34 1.16 1.96 0.93
BC-49 46 F BC, grade 2 0.49 3.19 1.19 1.84 0.62
BC-50 48 F BC, grade 3 0.68 3.29 0.88 1.39 0.68
BC-51 57 F BC, grade 1 0.71 2.82 0.93 1.43 0.50
BC-52 62 F BC, grade 2 0.66 2.48 0.87 1.50 0.59
BC-53 68 F BC, grade 2 0.98 2.81 0.84 1.37 0.55
BC-54 37 F BC, grade 1 0.65 2.29 0.84 1.49 0.95
BC-55 67 F BC, grade 1 0.73 2.35 0.89 1.50 0.71
BC-57 55 F BC, grade 1 0.86 3.40 0.89 2.04 0.69
BC-58 62 F BC, grade 1 0.52 3.25 0.95 2.05 0.57
BC-59 55 F BC, grade 1 0.45 2.69 0.82 1.62 0.88
BC-60 65 F BC, grade 2 0.65 2.86 0.97 1.61 0.49
BC-61 54 F BC, grade 2 0.54 2.66 0.88 1.63 0.96
BC-62 53 F BC, grade 2 0.49 2.65 0.77 1.37 0.72
BC-63 69 F BC, grade 1 0.62 2.73 1.05 1.81 0.58
BC-64 81 F BC, grade 1 0.6 2.62 0.84 1.37 0.47
BC-65 38 F BC, grade 2 0.58 2.35 0.95 1.70 0.87
BC-66 77 F BC, grade 1 0.46 2.46 0.83 1.44 0.57
BC-67 48 F BC, grade 1 0.43 1.87 0.86 1.52 0.66
BC-68 49 F BC, grade 2 0.42 2.49 0.65 1.73 0.73
BC-69 51 F BC, grade 1 0.41 2.00 0.84 1.70 0.49
Mean 57    0.49 2.40 0.94 1.70 0.80
± SD 12    0.23 0.63 0.19 0.49 0.32
  1. *Each indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Bold fonts indicate the unselected BC patients who revealed an adverse acute skin reaction to RT;
  2. aCase number was according to our files;
  3. bEarly skin reaction according RTOG score (Cox et al., 1995) [26]. RTOG grade: 1 - follicular, faint or dull erythema, dry desquamation; 2 - tender or bright erythema, moderate edema; 3 - confluent, moist desquamation, pitting edema; 4 - ulceration, haemorrhage, necrosis.
  4. Abbreviations used: N, normal; BC, breast cancer; F, female; n.d. indicates not determined.